About this trial
This prospective, randomized, single-center, study aims to evaluate the postoperative analgesic effectiveness of bilateral Rhomboid Intercostal Block (RIB) in patients undergoing elective bilateral breast prosthesis surgery. Effective postoperative pain management is essential to improve patient comfort and reduce opioid consumption.
Eligible patients aged 18-65 years with ASA physical status I-II will be randomly assigned to either receive ultrasound-guided bilateral RIB block in addition to standard general anesthesia or undergo surgery without any regional block (control group). All patients will receive standardized general anesthesia and postoperative patient-controlled analgesia (PCA) with intravenous tramadol.
The primary outcome of the study is total tramadol consumption within the first 24 postoperative hours. Secondary outcomes include postoperative pain scores at predefined time points, time to first analgesic requirement, need for rescue analgesia, incidence of nausea and vomiting, and block-related complications.
The results of this study will help determine whether bilateral RIB block provides superior postoperative pain control compared to standard analgesic management alone in bilateral breast prosthesis surgery.
Eligibility criteria
Qualifiers
Female patients aged 18-65 years
American Society of Anesthesiologists (ASA) physical status I-II
Scheduled for elective bilateral breast prosthesis surgery
Ability to understand the study protocol and provide written informed consent
Disqualifiers
Refusal to participate
Known allergy or hypersensitivity to local anesthetics (lidocaine or bupivacaine) or tramadol
Coagulation disorders or current anticoagulant therapy
Infection at the injection site
Trial design
Treatments tested in this trial
- Rhomboid intercostal plane block